Señales en vivo de GMAB | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 jun 2024 @ 14:42):
Our systems believe the stock currently is overvalued by 0.00% compare to its pairs and should correct downwards.

Stats
Volumen de hoy	248 661
Volumen promedio	489 906
Capitalización de mercado	16.76B
EPS	$20.29 ( Q1 \| 2024-05-02 )
Próxima fecha de ganancias	( $0.280 ) 2024-08-01
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	21.61 (Sector) 42.63 (Industry) 24.32
ATR14	$0.00700 (0.03%)

AADI -5.88%

ABCL 2.01%

ABCM 0.04%

ABEO -3.08%

ABIO -1.68%

ABOS 4.44%

ABSI 4.93%

ABUS -0.98%

ABVX -2.03%

ACAD -0.10%

ACER -17.95%

ACET -9.18%

ACGN 1.29%

ACHL -1.63%

ACHV 3.01%

ACIU -2.00%

ACLX 0.39%

ACRV -4.71%

ACST -4.89%

ACXP 3.69%

ADAG 6.12%

ADAP -2.98%

ADGI 0.87%

ADIL 0.88%

ADMA -2.04%

ADPT 0.44%

ADTX -2.78%

ADVM 0.43%

ADXN -1.60%

AEON -2.80%

AEZS -2.49%

AFMD -1.92%

AGEN -3.49%

AGIO -2.13%

AGLE 6.66%

AGTC 0.00%

AIKI 0.85%

AIMDW -13.88%

AKBA 4.66%

AKRO -2.85%

AKTX -2.38%

AKUS 0.00%

ALBO 0.00%

ALDX -1.80%

ALEC -0.89%

ALGS 1.32%

ALKS 1.45%

ALLK -11.44%

ALLO -3.97%

ALLR -3.85%

ALNA 3.16%

ALNY 2.90%

ALPN 0.02%

ALPX 0.00%

ALRN -2.24%

ALT -13.35%

ALVR -0.69%

ALXN 0.00%

ALXO -13.17%

ALZN 4.02%

AMRN -2.21%

AMTI -3.13%

ANAB 1.38%

ANEB 6.06%

ANGN 0.00%

ANIX -3.64%

ANL -0.14%

ANNX 2.40%

ANPC -3.15%

APGE 0.07%

APGN 8.48%

APGNW 30.65%

APLM -4.60%

APLS 0.92%

APLT -1.04%

APM 1.26%

APOP 0.38%

APRE 0.84%

APTO 4.82%

APTX 3.17%

APVO 0.93%

ARAV -13.39%

ARCT -5.60%

ARDS -12.13%

ARDX 1.16%

ARGX -0.37%

ARNA 0.00%

ARPO -0.90%

ARQT -3.02%

ARTL -2.50%

ARTLW 0.00%

ARVN 6.57%

ARWR -1.86%

ASLN -3.27%

ASMB -4.87%

ASND -2.05%

ATAI -3.13%

ATHA 7.31%

ATHE 0.56%

ATHX -33.50%

ATNF 0.99%

ATOS 4.81%

ATRA -3.48%

ATXI 2.70%

ATXS -0.66%

AUPH -0.99%

AURA 5.14%

AUTL -2.88%

AVBP -4.74%

AVEO 0.00%

AVIR -2.33%

AVRO -1.41%

AVTE 0.34%

AVTX -3.74%

AVXL -4.96%

AXLA 0.00%

AXSM -1.35%

AYLA 0.00%

AZRX 2.07%

BBI 2.17%

BBIO 2.27%

BCAB -2.61%

BCDA -3.15%

BCDAW -41.77%

BCEL 0.00%

BCLI 4.21%

BCRX 1.44%

BCTX 8.16%

BCTXW 13.02%

BCYC 1.15%

BDRX -3.80%

BDTX -0.43%

BEAM 2.60%

BFRA -2.91%

BGNE -2.07%

BIOR -5.27%

BIVI 2.90%

BLCM -6.68%

BLI -5.88%

BLPH 0.00%

BLRX -3.39%

BLTE -1.03%

BLU 0.03%

BLUE -2.03%

BMEA -13.05%

BMRN 0.19%

BNOX 6.15%

BNTC -1.69%

BNTX -1.65%

BOLD -8.47%

BOLT -0.09%

BPMC -1.15%

BPTH -1.90%

BPTS -13.47%

BRNS -0.37%

BRTX -6.10%

BTAI 16.92%

BTTX 20.00%

BTX 0.05%

BVXV 0.74%

BXRX 7.39%

BYSI 2.95%

CABA 0.83%

CADL 0.35%

CALA 0.00%

CALC -3.74%

CALT -1.59%

CAPR -1.29%

CARA -3.27%

CARM 7.39%

CASI -1.65%

CATB -6.97%

CBAY 0.03%

CBIO -2.65%

CBLI -7.31%

CBUS 0.56%

CCCC -2.34%

CCXI 0.00%

CDAK 0.00%

CDIO -4.99%

CDIOW 24.00%

CDMO -1.55%

CDMOP 0.04%

CDT -0.81%

CDTTW -39.60%

CDTX -6.53%

CDXC 7.38%

CDXS 8.97%

CELC -2.97%

CELU -1.83%

CELUW 11.80%

CERC -1.68%

CERE -1.52%

CERO -7.73%

CEROW -10.18%

CFRX -27.95%

CGEM -0.24%

CGEN -3.84%

CGON -1.42%

CGTX -4.35%

CHMA -6.00%

CHRS 4.11%

CINC 0.00%

CING -2.56%

CINGW 34.95%

CKPT -1.79%

CLBS -16.75%

CLDX -1.10%

CLGN 0.70%

CLLS -3.63%

CLNN 1.36%

CLNNW 0.00%

CLRB 7.06%

CLSD -2.40%

CLSN -0.68%

CLVS 0.00%

CMMB -3.89%

CMND 5.65%

CMPI 0.00%

CMPX -0.95%

CMRA 0.00%

CMRAW 33.33%

CMRX -4.43%

CNCE 0.00%

CNSP -35.40%

CNST 0.00%

CNTA 0.00%

CNTB -0.75%

CNTX -4.78%

COCP -2.00%

COEPW 32.45%

COGT -2.64%

CORT 2.24%

COYA -0.81%

CPRX -1.95%

CRBP -0.95%

CRBU -6.53%

CRDF 1.33%

CRGX 0.27%

CRIS -3.19%

CRNX -6.36%

CRSP -0.29%

CRTX 2.63%

CRVO -3.25%

CRVS 0.56%

CSBR 0.11%

CTCX -1.59%

CTIC 0.06%

CTMX -2.90%

CTNM 2.01%

CTXR 0.24%

CUE -1.04%

CVAC -9.18%

CVKD -2.34%

CWBR 2.80%

CYAD -12.96%

CYCC 8.49%

CYCCP 5.28%

CYCN 7.81%

CYT -2.27%

CYTK -2.69%

CYTO 0.90%

DARE 3.55%

DAWN -1.04%

DBTX -0.81%

DBVT 4.17%

DFFN 10.28%

DICE 0.06%

DMAC 30.09%

DNLI -1.79%

DNTH -4.74%

DOMH 1.59%

DRMA -2.57%

DRMAW -1.25%

DRNA 0.00%

DRTS 1.85%

DRTSW 0.00%

DRUG 1.43%

DSGN -3.17%

DTIL -0.24%

DYAI 9.68%

EARS -1.77%

EDIT -2.82%

EDSA 4.09%

EFTR 3.51%

EFTRW -53.85%

EIGR -9.21%

ELAB -3.01%

ELDN 8.82%

ELEV -3.73%

ELOX 10.77%

ELTX -5.15%

ELVN -1.77%

ELYM 4.60%

ENGN -0.25%

ENGNW 0.00%

ENLV 0.00%

ENOB 1.79%

ENSC 6.53%

ENTA 0.16%

ENTO -4.97%

ENTX -0.53%

ENVB 8.30%

EPIX -0.73%

EPRX -1.92%

EPZM 0.00%

EQ 0.32%

EQRX -2.09%

EQRXW 0.00%

ERAS -0.24%

ERNA -2.83%

ERYP 1.30%

ESLA 4.30%

ESLAW 16.64%

ETNB -3.94%

ETON 3.35%

ETTX 0.00%

EVAX -0.71%

EVGN 4.76%

EVLO 0.00%

EWTX -1.55%

EXAI -0.20%

EXEL 0.43%

EYEG -0.69%

EYEN 0.68%

EYPT 1.45%

FATE -11.42%

FBIO 0.90%

FBIOP 0.87%

FBLG -8.00%

FBRX -0.02%

FDMT -4.82%

FENC -2.74%

FGEN -9.83%

FHTX 7.82%

FIXX 0.77%

FMTX 0.00%

FNCH 0.00%

FOLD -1.52%

FREQ 4.76%

FRLN 0.15%

FRTX 0.00%

FSTX 0.00%

FTRE 0.85%

FULC 1.84%

FUSN 0.00%

FWBI 4.59%

FWP 0.00%

GALT 0.00%

GANX -3.70%

GBIO -2.12%

GBT 0.01%

GDTC 0.50%

GERN -3.87%

GHRS -3.72%

GLMD -4.09%

GLPG -1.52%

GLSI 3.97%

GLTO -3.31%

GLUE -3.43%

GLYC -12.17%

GMAB -0.23%

GMDA -18.25%

GMTX 0.00%

GNCA -85.71%

GNFT -2.60%

GNLX -4.64%

GNPX -3.43%

GNTA 3.94%

GOSS -11.57%

GOVX -1.82%

GOVXW 10.89%

GPCR -6.39%

GRAY -10.80%

GRCL 0.05%

GRNA -0.03%

GRNAW 8.91%

GRPH -2.75%

GRTS 0.48%

GRTX -1.66%

GTHX -0.91%

GUTS 3.00%

GXGXW 41.67%

GYRE -4.44%

HALO -1.74%

HARP 0.09%

HCWB -6.13%

HEPA -3.14%

HGEN -84.62%

HILS 5.66%

HLVX -1.91%

HOOK 0.89%

HOTH -1.62%

HOWL -0.43%

HRMY 4.36%

HRTX 8.69%

HSTO 0.00%

HUMA 1.22%

HUMAW -6.26%

IBRX -5.36%

ICCC -4.42%

ICPT 0.21%

ICU 19.49%

ICUCW 20.20%

ICVX -0.91%

IDRA -23.04%

IDYA -3.07%

IFRX -2.47%

IGMS -1.31%

IKNA -0.30%

IKT -6.03%

IMAB 0.00%

IMCR -3.16%

IMGN 0.02%

IMGO 0.00%

IMMP 4.58%

IMMX -5.65%

IMNM 3.11%

IMNN 0.91%

IMPL -27.27%

IMRA 15.96%

IMRN -0.40%

IMRX -3.50%

IMTX -1.25%

IMTXW 6.00%

IMUX 1.85%

IMV 0.00%

IMVT -3.48%

INAB -1.68%

INBX -2.05%

INCY -2.16%

INDP 8.49%

INFI -52.38%

INKT 2.10%

INM 0.04%

INMB 4.46%

INO 2.86%

INSM -0.99%

INTS -1.96%

INVA 0.15%

INZY 1.83%

IOBT -10.24%

IONS 1.07%

IOVA -2.66%

IPA 3.00%

IPHA 3.05%

IPSC -2.34%

IRON -2.63%

ISEE 0.38%

ITOS 0.82%

ITRM 2.33%

IVA 6.96%

IVVD 0.41%

JAGX 1.31%

JANX -4.53%

JAZZ -1.01%

JNCE 0.00%

JSPR -2.86%

JSPRW 20.88%

JUNS 0.00%

JUNSW 0.00%

KA -2.45%

KALV -4.07%

KDNY 0.22%

KMPH -0.34%

KNSA -1.98%

KNTE -0.38%

KOD -7.91%

KPRX -4.08%

KPTI -7.37%

KRBP -10.00%

KRON 0.62%

KROS -0.55%

KRRO -0.36%

KRTX 0.03%

KRYS -0.02%

KTRA 7.64%

KTTA -0.65%

KTTAW 0.92%

KURA -0.05%

KYMR -2.83%

KYTX -3.23%

KZIA 4.41%

KZR -0.14%

LABP 0.57%

LBPH -0.54%

LBPS 0.00%

LBPSW 14.81%

LEGN 0.98%

LENZ -2.60%

LEXX -1.56%

LEXXW -14.63%

LGND -1.28%

LGNDV 0.00%

LGVN -9.37%

LIAN -8.28%

LIFE 2.70%

LIPO -5.10%

LIXT -9.76%

LIXTW 46.21%

LJPC -0.32%

LMNL 0.12%

LOGC 1.48%

LPCN -3.68%

LPTX -2.45%

LQDA 0.24%

LRMR 0.21%

LSTA -1.68%

LTRN 6.06%

LUMO 1.79%

LVTX -2.58%

LXEO -8.83%

LXRX -2.06%

LYEL -35.63%

LYRA 1.94%

MACK 0.10%

MBIO -11.02%

MBRX -2.03%

MCRB 3.04%

MDGL -2.79%

MDNA -13.16%

MDWD 2.81%

MDXG -2.36%

MEIP 0.00%

MESO -1.48%

MGNX -5.36%

MGTA -7.74%

MGTX -0.95%

MGX 0.27%

MIRM 0.00%

MIRO 0.59%

MIST 3.84%

MITO 0.00%

MLEC -7.68%

MLECW 2.31%

MLND -5.36%

MLTX 0.38%

MLYS -6.08%

MNKD -0.76%

MNMD 3.82%

MNOV 2.11%

MNPR -8.63%

MOLN 2.46%

MOR 0.45%

MORF -3.25%

MREO -2.57%

MRKR -0.42%

MRNA -8.58%

MRNS -6.99%

MRSN -2.62%

MRTX -0.17%

MRUS -0.75%

MRVI -1.02%

MTCR -1.29%

MTEM 6.93%

MTP -18.50%

MURA -4.02%

MYMD 1.08%

NAMS 0.48%

NAMSW -0.21%

NAUT 1.11%

NBRV 0.71%

NBSE -1.56%

NBTX 12.09%

NCNA 1.81%

NERV -1.58%

NEXI -0.74%

NGM -1.28%

NGNE 3.70%

NKGN 10.84%

NKGNW 8.00%

NKTR 3.27%

NKTX -4.40%

NLSP 3.24%

NLSPW 26.67%

NMRA -1.37%

NMTR -42.97%

NOVN -24.84%

NRBO 14.32%

NRIX -0.67%

NRSN -4.82%

NRSNW 0.00%

NRXP -8.18%

NRXPW 18.33%

NRXS -1.20%

NTBL 2.63%

NTEC -12.45%

NTHI 0.00%

NTLA -5.33%

NTRBW -31.07%

NUVL -1.62%

NVAX -7.50%

NVCT -7.75%

NVIV -34.28%

NXTC -4.11%

NYMX -0.05%

OABI 2.87%

OABIW -10.06%

OBIO -1.17%

OBSV 0.00%

OCEA -1.76%

OCGN 9.90%

OCS -1.00%

OCUL 0.76%

OCUP 0.65%

ODT -4.27%

OKYO 2.15%

OLMA -5.20%

OMER -3.08%

OMGA 1.25%

ONCO 6.08%

ONCR -3.08%

ONCS 31.87%

ONCT -2.35%

ONCY 3.45%

ONTX -0.47%

ONVO 0.29%

OPNT 0.00%

OPT 2.06%

ORGS 1.19%

ORIC -1.04%

ORMP 18.30%

ORPH 0.00%

ORTX 0.30%

OSMT -1.77%

OTIC -92.64%

OTLK -1.66%

OVID 0.01%

OYST 0.00%

PALI -0.22%

PASG 2.63%

PBLA -7.50%

PBM -2.46%

PBYI 3.04%

PCSA -1.93%

PCVX 0.58%

PDSB -6.32%

PEPG 1.55%

PGEN -5.80%

PHAR 2.19%

PHAS 0.00%

PHAT -0.48%

PHIO -3.58%

PHIOW 36.47%

PHVS -5.83%

PHXM -5.20%

PIRS 0.58%

PKBO 0.00%

PKBOW 999 900.00%

PLRX -1.92%

PLUR 7.39%

PMN -5.55%

PMVP -1.79%

PNT 0.16%

PPBT -6.43%

PRAX 6.70%

PRDS 0.93%

PRLD -2.64%

PROG -3.47%

PROK -0.41%

PRQR 1.21%

PRTA -2.69%

PRTC 0.41%

PRTG 0.97%

PRTK 1.83%

PRVB 0.00%

PSTI -2.91%

PSTV -14.04%

PSTX -2.52%

PTCT -0.60%

PTE -0.82%

PTGX -0.76%

PTIXW -48.41%

PULM 1.53%

PXMD 4.76%

PYPD 1.71%

PYXS 4.43%

QLGN -5.70%

QNCX 5.70%

QNRX -0.49%

QSI -34.10%

QSIAW -3.13%

QTTB -0.14%

QURE -0.34%

RAIN -1.63%

RANI 4.81%

RAPT -1.62%

RARE 1.93%

RCKT -9.01%

REGN -0.47%

RENB -2.45%

REPL -1.70%

RETA 0.02%

REUN -0.89%

REVB -1.40%

REVBU 3.46%

REVBW 5.00%

RGLS -5.84%

RGNX -6.49%

RIGL -6.68%

RLAY -4.75%

RLMD -1.34%

RLYB -4.70%

RNA 1.03%

RNAC -4.45%

RNAZ 0.00%

RNXT 0.88%

ROIV -1.71%

ROIVW 4.56%

RPHM -1.24%

RPRX -0.63%

RPTX -0.44%

RUBY 2.70%

RVLP -32.05%

RVMD -0.49%

RVMDW -29.90%

RVNC -0.64%

RVPH -1.07%

RVPHW -5.28%

RXDX 0.09%

RXRX -5.54%

RYTM -5.72%

RYZB 0.02%

RZLT 2.56%

SABS -1.37%

SABSW -11.81%

SAGE 0.46%

SANA -3.32%

SAVA -1.61%

SAVAW 0.00%

SBBP 1.52%

SBTX 1.03%

SCNI 0.32%

SCPH 10.86%

SCPS 0.00%

SEEL -3.10%

SEER 0.29%

SELB -8.00%

SESN 7.29%

SGEN -0.07%

SGMO -0.60%

SGMT -4.83%

SGTX -2.56%

SIOX 22.63%

SLDB -1.39%

SLGL 5.23%

SLN -7.27%

SLNO -0.44%

SLRX -0.40%

SLS -3.42%

SMMT -3.75%

SNDX 3.22%

SNGX -0.38%

SNPX -3.24%

SONN -0.01%

SPPI -0.49%

SPRB -1.59%

SPRC -4.25%

SPRO 0.75%

SRNE 0.00%

SRPT -1.39%

SRRA 0.00%

SRRK -1.61%

SRZN -2.45%

STAB 0.00%

STOK -6.88%

STRO -2.01%

STSA 0.00%

STTK 6.05%

SURF -0.93%

SVRA -1.71%

SWTX -0.16%

SYBX 1.29%

SYRS -1.98%

TALS -0.73%

TARA -7.62%

TARS -2.09%

TBPH 0.71%

TCBP 4.11%

TCDA 0.00%

TCON 0.00%

TCRR 0.00%

TCRT -1.75%

TCRX 4.20%

TECH -0.71%

TENX -0.32%

TERN -9.52%

TFFP -7.61%

TGTX -6.77%

THRX 0.12%

TIL -1.09%

TLC 0.00%

TLSA -7.74%

TNGX -3.56%

TNXP -6.00%

TNYA -4.91%

TPST 5.83%

TRDA -4.54%

TRVI 2.68%

TRVN 0.82%

TSHA -18.86%

TSVT -4.79%

TTNP -6.05%

TVTX 3.02%

TYRA -6.95%

UBX -2.55%

UNCY -4.20%

URGN 1.79%

UTHR 0.10%

VACC 11.36%

VALN -6.70%

VAXX 118.69%

VBIV 0.93%

VBLT -8.77%

VCEL 0.99%

VCNX 9.03%

VCYT -0.88%

VERA -6.03%

VERU 1.19%

VERV -2.49%

VIGL -1.88%

VINC 0.78%

VIR -0.49%

VIRI -4.53%

VIRX 3.98%

VKTX -1.78%

VLON -13.04%

VNDA -3.99%

VOR -6.05%

VRCA 0.00%

VRDN -3.84%

VRNA -1.63%

VRPX 1.02%

VRTX -0.01%

VSTM 3.57%

VTGN -1.66%

VTVT 0.39%

VTYX -2.72%

VXRT -2.06%

VYGR -0.77%

VYNE -4.29%

VYNT 7.78%

WINT -0.60%

WVE -8.18%

XBIO 1.03%

XBIT 7.29%

XCUR 3.77%

XENE -1.89%

XERS 4.52%

XFOR 5.73%

XLO 3.37%

XLRN 0.00%

XNCR 0.21%

XOMA -9.36%

XOMAO -0.45%

XOMAP -0.82%

XRTX -7.96%

YMAB -1.71%

ZGNX 0.00%

ZIOP -0.88%

ZLAB -3.78%

ZNTL -1.79%

ZSAN 0.00%

Correlación (AI algo v.1.1b): Overvalued: 0.00% $25.72 paired level. (El Algoritmo Rastrea Los Cambios De Las Acciones Más Correlacionadas En Tiempo Real Y Proporciona Una Actualización Instantánea)

Volumen Correlación

Largo: -0.15 (neutral)

Corto: 0.36 (neutral)

Signal:(45.313) Neutral

Genmab A/S Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Genmab A/S Correlación - Moneda/Commodity

0.34
( neutral )

-0.69
( moderate negative )

0.00
( neutral )

-0.63
( weak negative )

0.43
( neutral )

-0.36
( neutral )

Genmab A/S Finanzas

Annual	2023
Ingresos:	$16.47B
Beneficio Bruto:	$15.92B (96.64 %)
EPS:	$66.64

FY	2023
Ingresos:	$16.47B
Beneficio Bruto:	$15.92B (96.64 %)
EPS:	$66.64

FY	2022
Ingresos:	$14.60B
Beneficio Bruto:	$14.60B (100.00 %)
EPS:	$83.38

FY	2021
Ingresos:	$8.48B
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$4.60

Financial Reports:

No articles found.

Genmab A/S Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.